Should You Invest in SPACs? (Part 2)

Special purpose acquisition companies -- commonly known as "SPACs" -- are becoming increasingly popular in recent years as a way for companies to reach the public markets. While there were only 59 companies that chose to do a "SPAC IPO" in 2019, more than 360 have already taken place thus far in 2021. The total value of funds raised from those SPAC IPOs this year has exceeded $112 billion, and there are reportedly more than 300 more SPACs that have raised funds and are looking for a target. But what will the modern SPAC Race mean for investors? Is this indeed a more capital-efficient way for companies to raise money and go public? Or are investors throwing money at an unproven and potentially dangerous new trend? To answer those questions, 7investing Lead Advisors Simon Erickson and Steve Symington are digging deeper into the recent SPAC craze. In part two of their two-part podcast series, Simon and Steve dig deeper in the way that SPACs are structured and present the important factors that investors should consider. They also take a look at four SPACs that have gained a lot of attention this year -- SoFi, Ginkgo Bioworks, OpenDoor, and Rocket Lab -- and evaluate each of them as potential investment ideas. Publicly-traded companies mentioned in this podcast include Bayer, OpenDoor, SoFi, Vector Acquisition Corp, and Virgin Galactic. 7investing Lead Advisors may have positions in the companies that are mentioned. This interview was originally recorded on July 14th, 2021. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Follow us on Social Media ► https://www.facebook.com/7investing/ ► https://twitter.com/7investing ► https://instagram.com/7investing